Dror Ortho-Design Reports $759K Net Loss and Deteriorating Financial Position in Latest Filing

Dror Ortho-Design, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending June 30, 2025. The company recorded a net loss of $759,338 for the three months ended June 30, 2025, a decrease from a loss of $1,506,790 in the same period the previous year. For the first half of 2025, the net loss was $1,335,461, down from $2,815,253 in the first half of 2024. Total operating expenses for the second quarter were $731,539, a substantial reduction from $1,496,918 in the prior year, primarily due to a significant decrease in share-based compensation expenses, which fell by 98% to $15,977.

The company’s financial position has deteriorated, with total assets dropping to $132,616 as of June 30, 2025, compared to $662,725 at the end of 2024. Current liabilities surged to $1,639,241, up from $906,738, largely due to increased accounts payable and the introduction of notes payable totaling $300,513. This has resulted in a stockholders' deficit of $1,664,285, compared to a deficit of $367,994 at the end of the previous fiscal year.

Strategically, Dror Ortho-Design has been focused on developing its proprietary orthodontic alignment platform, which is still in the research and development phase and has not yet generated revenue. The company has made efforts to raise capital, securing $500,000 through loans in the first half of 2025, and is exploring additional fundraising opportunities. The company’s workforce remains stable, with no significant changes in employee headcount reported.

Operationally, the company has not yet achieved product commercialization, and its future success hinges on obtaining regulatory approvals and market acceptance of its platform. The company is preparing to apply for FDA clearance for its updated orthodontic device, which is expected to be a key milestone. Management has expressed concerns about the company's ability to continue as a going concern, given its reliance on external financing and the absence of revenue generation.

Looking ahead, Dror Ortho-Design anticipates continued operating losses as it invests in product development and regulatory processes. The company plans to allocate approximately $2.5 million over the next 18 months for software and hardware development, as well as for securing necessary regulatory approvals. The management remains cautious about the future, emphasizing the need for additional capital to sustain operations and achieve its strategic objectives.